Physician profile
John D Crompton
NPI 1013968742
$77,836.30
in general payments reported to CMS, 2019-2025
15 companies · $65.38 in 2025
The $65.38 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $20K · 2021: $8,632 · 2022: $1,541 · 2023: $15.46 · 2024: $135 · 2025: $65.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $216.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corentec America INC | $75,637.10 | 2019-2021 | |
| Lima USA, INC. | $1,442.00 | 2022 | |
| Abbott Laboratories | $162.58 | 2021-2022 | |
| Pacira Therapeutics, INC. | $157.17 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $70.48 | 2019-2021 | |
| Pacira Pharmaceuticals Incorporated | $57.54 | 2022 | |
| Organogenesis INC. | $53.77 | 2024 | Affinity |
| Si-Bone, INC. | $48.66 | 2020-2024 | |
| Endo USA, INC. | $44.25 | 2025 | Xiaflex |
| Convatec INC. | $38.26 | 2024 | |
| Medtronic USA, INC. | $33.59 | 2019-2020 | |
| Smith+Nephew, INC. | $29.69 | 2019 | |
| Kerecis Limited | $24.62 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Vertex Pharmaceuticals Incorporated | $21.13 | 2025 | |
| Paratek Pharmaceuticals, INC. | $15.46 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Crompton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.